The International Diabetes Closed Loop (iDCL) Trial: Protocol 1

Overview

Información sobre este estudio

The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year
  2. Use of an insulin pump for at least 6 months
  3. Age ≥14 years old
  4. HbA1c level <10.5% at screening
  5. For females, not currently known to be pregnant
  6. Willingness not to add glucose-lowering agents (such as Pramlintide, Metformin, GLP-1 analogs, SGLT2 inhibitors) during the study
  7. Willingness, if not assigned to the closed-loop group, to avoid use of any closed-loop control system for the duration of the clinical trial
  8. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the unblinded study CGM is in use
  9. Willingness to establish network connectivity on at least a weekly basis either via local Wifi network or via a study-provided cellular service
  10. Currently using no insulins other than one of the following rapid-acting insulins at the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine (Apidra)
  11. Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol
  12. For subjects less than 18 years old, living with one or more parent/legal guardian (referred to subsequently as diabetes care partner) committed to participating in study training for emergency procedures for severe hypoglycemia and able to contact the subject in case of an emergency

Exclusion Criteria:

  1. Medical need for chronic acetaminophen
  2. Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs, SGLT2 inhibitors) in the 3 months prior to enrollment
  3. Hemophilia or any other bleeding disorder
  4. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk including any contraindication to the use of any of the study devices per FDA labeling
  5. Participation in another pharmaceutical or device trial at the time of enrollment or during the study
  6. Use of a closed-loop system within the last month prior to enrollment
  7. Employed by, or having immediate family members employed by TypeZero Technologies, LLC

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Yogish Kudva, M.B.B.S.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20363252

Mayo Clinic Footer